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Numerous in vitro and animal studies suggest that methotrexate 
(MTX) and 5-fluorouracil (5FU), used in sequence, are more tumorcidal 
than either drug alone or in conventional combinations. The data sug¬ 
gest a sequential delay of 24 hours to be most effective against breast 
cancer. Twenty-three patients with diverse advanced malignancies were 
treated with a total of 127 courses of an every 2-3 week regimen con¬ 
sisting of oral MTX 50 mg/m^ every six hours for five doses followed 
one hour after the last dose by intravenous 5FU 600 mg/m^. Oral leuko- 
vorin 10 mg/m^ was begun six hours after the last MTX dose and con¬ 
tinued every six hours for six doses. In addition, three of these 
patients received a total of eight courses of a regimen consisting of 
oral MTX 8 mg/m^ every six hours for five doses, followed by 5FU as 
above, and without leukovorin rescue. Twenty-one of the 23 patients 
had received prior chemotherapy, including 12 who had previously 
received one-hour sequential MTX-5FU therapy. Four of the eight breast 
cancer patients evaluable for their response to the therapy showed 
minimal responses. Three of the four evaluable colorectal cancer 
patients showed minimal responses. Prior therapy with MTX-5FU contain¬ 
ing regimens seemed to decrease the likelihood of a response to the 
24-hour regimen among breast cancer patients. Toxicity was mild and 
not life-threatening for all 135 treatment courses except the first 
two courses in one patient, which resulted in severe leukopenia and 
infection. Fifty-seven percent of the treatment courses resulted in 




far the most common side-effects, occurring after 17.8 percent and 
14.9 percent of the treatment courses, respectively. No other side- 
effect occurred more than ten percent of the time. Mild nausea and 
vomiting, diarrhea, mucositis, thrombocytopenia, and nephrotoxicity 
each occurred after eight to ten percent of the treatment courses. 
Toxicity did not correlate with elevated serum MTX levels. Retreat¬ 
ment was delayed but drug dosages were not altered for those patients 
manifesting toxic side-effects. Micromolar serum MTX levels were sus¬ 
tained over 24 hours by the oral, divided-dose schedule, which was 
very convenient for the outpatient population studied. Based on these 
results, it appears that larger trials with drug regimens using oral, 




Breast cancer is the most common cause of cancer deaths among 
women in the U.S. (42). One of thirteen American women eventually 
develops it, and more than half of these die from it. Moreover, the 
overall mortality rate has shown little improvement for several dec¬ 
ades. Chemotherapy for the disease, as an adjuvant to surgical resec¬ 
tion of the primary tumor, to treat presumed systemic micrometastases, 
was first attempted with a multitude of single agent therapies in the 
1960's. Bisel (11) has compiled the response rates to many of these 
single agents, as summarized in Table 1. No single agent had a 
response rate of more than 38 percent. 
Combination-agent chemotherapy has been widely used ever since 
Cooper (21) in 1969 reported a dramatic 90 percent response rate in 
60 patients treated with CMFVP (cyclophosphamide, methotrexate, 5- 
fluorouracil, vincristine, and prednisone). Eleven subsequent studies 
of this regimen in the early 1970's, however, showed an overall 
response rate of 47 percent in 529 cases, with a range of response 
rates from 20 to 70 percent (17, 18). 
Still, this was clearly an improvement over single-agent therapy, 
and the search began for even more effective drug regimens. Most of 
the regimens tried were modifications of Cooper's original CMFVP proto¬ 
col, usually omitting the vincristine and/or prednisone. Bisel (11) 
cites five studies using CMF alone, with response rates from 48 percent 
to 64 percent; the CMF regimen became one of the most popular for the 










I. Alkylating Agents 
Cyclophosphamide 529 182 34% 
Nitrogen Mustard 92 32 35 
Thio-TEPA 162 48 30 
II. Antimetabolites 
5-Fluorouracil 1263 324 26 
Methotrexate 356 120 34 
Arabinosyl Cytosine 64 6 9 
Hydroxyurea 16 2 12 
III. Antitumor Antibiotics 
Adriamycin 193 67 35 
Mitomycin-C 60 23 38 
IV. Mitotic Inhibitors 
Vincristine 226 47 20 
Vinblastine 95 19 20 
V. Random Synthetics 
Hexame thylmelamine 39 11 28 
Methyl CCNU 33 2 6 
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included: a CMFP regimen studied by Canellos et. al. (16), which 
produced a 68 percent response rate in 40 patients, eight of whom had 
complete remissions, and which increased median survival from four 
months in non-responders to 18 months in responders; a CAF (cyclophos¬ 
phamide, adriamycin, 5-fluorouracil) regimen which showed a 73 percent 
response rate (42); and a CAV regimen with a 72 percent response rate 
and a 22-month median response duration (42). Biran (10) showed that, 
for CMF therapy, the percentage of patients responding, the median 
response duration, and the reported toxic side-effects all vary 
directly with the drug dosages employed. Toxic side-effects include 
nausea, vomiting, leukopenia, thrombocytopenia, stomatitis, and alo¬ 
pecia . 
Besides toxicity, CMF therapy for breast cancer has other draw¬ 
backs. In a Milan study (42), its benefits seemed confined to pre¬ 
menopausal women. In a study by Chang (19), 14 of 16 (88 percent) 
patients with estrogen-receptor (ER) positive tumors responded to CMF 
therapy, with a median response duration of 17 months and a median sur¬ 
vival of 27 months. However, only 7 of 20 (35 percent) patients with 
ER-negative tumors responded to the same therapy, with a median 
response duration of only 7 months and a median survival of only 9 
months. 
Furthermore, Chlebowski et. al. (20) have shown that, at least 
for 121 patients with metastatic breast cancer treated with a regimen 
of CMFP with triiodothyronine, those randomized to receive combination 
chemotherapy show significantly increased response frequency and 
response duration, but not significantly increased survival, compared 
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with those randomized to receive the regimen as single drugs admini¬ 
stered sequentially. Indeed, a common complaint about chemotherapy 
for breast cancer is that it achieves increasing numbers of responses 
but has not greatly altered survival statistics. Clearly there is 
room for improvement. 
One idea for improving therapeutic results has been to optimize 
the scheduling of drugs in a chemotherapeutic regimen, rather than 
simply administering all the drugs at once or giving them as single 
agents, sequentially. For most of the drugs used to treat breast can¬ 
cer, which act at independent sites on a cell's metabolism or division, 
the importance of proper scheduling is less obvious than it is for two 
widely-used antimetabolites, methotrexate and 5-fluorouracil, which act 
on sequential steps in folic acid metabolism. 
Methotrexate (MTX), whose structure is as shown, is a folic acid 
analog, and, as such, a tightly binding competitive inhibitor of 
Figure 1. Methotrexate 
dihydrofolate reductase, the enzyme which reduces dihydrofolic acid 
(DHF) to tetrahydrofdate (THF); THF is critically important for the 
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transfer of one-carbon units in many reactions, including the bio¬ 
synthesis of inosinic acid (IMP), a precursor of adenine and guanine 
nucleotides. Hence, methotrexate inhibits de novo purine synthesis. 
As a result, it is toxic to tissues in which DNA synthesis and turnover 
are rapid, including certain cancers, gastrointestinal mucosa, and bone 
marrow. Methotrexate's gastrointestinal toxicity manifests itself 
first as a swelling and vacuolization of the mucosal cells of the 
intestinal epithelium, followed by desquamation of these cells, extru¬ 
sion of plasma into the bowel lumen, and, finally, hemorrhagic desqua¬ 
mating enteritis (28) . The patient treated with MTX may therefore 
experience anorexia, nausea and vomiting, ulcerative stomatitis, 
diarrhea, bloody diarrhea, and, rarely, intestinal perforation. The 
bone marrow toxicity manifests itself as leukopenia, anemia, and/or 
thrombocytopenia. Other, less common, toxic side-effects of MTX may 
include alopecia, dermatitis, hepatotoxicity, and nephrotoxicity. It 
is cleared by the kidneys, both by glomerular filtration and active 
tubular secretion. 
Leukovorin (5-formyl tetrahydrofolate), a fully-reduced, meta- 
bolically active THF analog, is often used to "rescue" patients receiv¬ 
ing MTX from the toxic side-effects by acting beyond the dihydrofolate 
reductase step blocked by MTX, 
5-Fluorouracil (5FU) whose structure is as shown, is a pyrimidine 
analog; it is metabolized to 5-fluorouridine monophosphate (5FUMP) and 
then to its active form, 5-fluoro-2'-deoxyuridine monophosphate (5FdUMP) 




Figure 2. 5-Fluorouracil 
ribose-1- 
phosphate 





-> 5F dUMP 
Figure 3. Metabolism of 5FU 
Step "a" requires 5-phosphoribosy 1-1-pyrophosphate (PRPP) and ©rotate 
phosphoribosy1 transferase. Steps "b" and "c" are catalyzed by uridine 
phosphorylase and uridine kinase, respectively. Steps "d" and "e" 
form an alternative pathway catalyzed by thymidine phosphorylase and 
thymidine kinase, respectively. 
The 5FdUMP inhibits DNA synthesis by inhibiting thymidylate syn¬ 
thetase, the enzyme which promotes methylation of deoxyuridylic acid 
(dUMP) to thymidylic acid (dTMP); the dTMP would later be incorporated 
into DNA as dTTP. 5FdUMP does this by forming a covalently bound ter¬ 
nary complex with thymidylate synthetase and N^>^-methylenetetrahydro- 
folate; the postulated structure is as shown (45,50): 

A - 
Figure 4. 5FdUMP Ternary Complex 
In the presence of N^-^-methylene-THF, 5FdUMP binds thymidylate 
synthetase 7-8 orders of magnitude more tightly than without the co¬ 
factor (50); the cofactor is essentially necessary for binding and 
inhibition of the enzyme by 5FdUMP to occur. 
Additionally, 5FU may compete with uracil by being incorporated 
as 5FUTP into RNA, thereby inhibiting RNA and protein synthesis. 
Since 5FU is, like methotrexate, an inhibitor of DNA synthesis, 
the toxic side-effects of 5FU are essentially the same as those of MTX. 
Maximal hematologic effects are seen 9-14 days out from treatment. 
5FU is degraded in the liver to 5-fluoro-5,6-dihydrouracil, the ring 
of which is opened to yield o(.-fluoro-^-ureidoproprionic acid, which is 
then converted to *-fluoro-p-alanine (28). 
MTX and 5FU are often used together. Their combined effects have 
been the subject of much controversy and research. Some early workers 
(23) proposed that the two combined have the effect of suppressing 
humoral antibody production without concomitant inhibition of cell- 
mediated immunity. Most of the research, however, has been devoted to 
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each drug's effects on the other's ability to inhibit DNA biosynthesis. 
The two drugs act at sequential steps in folic acid metabolism, as 
shown below in a figure adapted from Tattersall (48): 
<■'« V>©.-\ u c\«c-bc<Je 






Several workers have found that MTX and 5FU, when given together, 
actually antagonize each other to yield less than additive or even 
less than single-agent cytotoxic effects: Waxman and Bruckner (53) 
found this in cultured human bone marrow, Friend leukemia cells, and 
L1210 mouse leukemia cells; Ullman et. al. (50) found this in cultured 
L1210 mouse leukemia cells when low-dose, but not high-dose, MTX pre¬ 
ceded 5FU by two hours; Tattersall et. al. (48) found this in L5178Y 
cells in vitro when MTX and 5FU were given either simultaneously or 
with one drug preceding the other by six hours; and Tattersall et. al. 
also found this in vivo in mice bearing L1210 leukemia cells, where the 
effect of drug scheduling was not studied. 
Several theories were proposed to explain these findings: 
(1) Tattersall et. al. found that MTX causes an accumulation of 
3 
label from H-deoxyuridine in dUMP, suggesting that MTX causes an 
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increased dUMP pool, which competitively reduces the effect of 5FdUMP 
to inhibit thymidylate synthetase. 
(2) Alternatively, the increased dUMP pool may have a feedback 
inhibitory effect on the enzymes which activate 5FU and 5FdUMP. 
(3) Ullman et. al. proposed that inhibition of DHF reductase by 
MIX results in an accumulation of DHF and a consequent depletion of 
intracellular THF and therefore of ^-methylene THF, which is 
necessary for inhibition of thymidylate synthetase by 5FdUMP, the active 
form of 3FU. They found that the intracellular amount of 5FdUMP cova¬ 
lently bound to thymidylate synthetase is greatly diminished in cells 
deprived of folate cofactors, but that leukovorin will increase the 
cytotoxicity of 5FU in these folate-deprived cells by a factor of 5. 
Despite these theories, the great majority of studies on the com¬ 
bined effects of methotrexate and 5-fluorouracil have found that the 
two agents in fact complement each other to yield synergistic cyto¬ 
toxic effects. The earliest workers studied the effects of the two 
drugs given simultaneously. Kline et. al. in 1966 (34) demonstrated 
a synergistic increase in the survival time of mice with advanced leu¬ 
kemia L1210 when they were treated daily with MTX and 5FU. Waxman et. 
al. (52) showed that, for L1210 cells, maximal effects on de novo DNA 
synthesis are produced by MTX concentrations of 1 x 10"^ M and 5FU 
concentrations of 3.1yng/ml. 
Numerous later workers studied the effect of scheduling of MTX 
and 5FU. In 1976, Martin et. al. (36) reported that MTX-5FU shows 
synergistic toxicity against CD8F1 mammary cancer cells only when MTX 
is given one hour prior to 5FU. Shortly thereafter, Bertino et. al. (7) 
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showed that, for sarcoma 180 in mice, only when MTX precedes 5FU does 
survival significantly exceed that of mice treated with MTX alone; 
optimal results are obtained with pre-treatment intervals of one to 
four hours. Lee et. al. (35) showed that, for postoperative therapy 
of mammary adenocarcinoma 13762 in female Fischer rats, MTX followed 
six hours later by 5FU is superior to simultaneous MTX-5FU, single¬ 
agent 5FU, and 5FU followed by MTX in achieving the longest survivals 
and the lowest number of lung metastases. Heppner et. al. (31) showed 
that, for mammary cancer in mice, MTX and leukovorin (LV) followed in 
one hour by 5FU is far more effective than all three agents given 
simultaneously or 5FU followed by MTX/LV, as assayed by mean survival 
time. Donehower et. al. (24) showed that, for human breast cancer 
cells in vitro, an MTX-5FU regimen is most effective, with additive 
cytotoxic effects, when MTX is given four hours prior to, two hours 
prior to, or simultaneously with the 5-FU. The administration of 5FU 
two or four hours prior to MTX decreases the cytotoxicity of the com¬ 
bination. Brown et. al. (12) showed that, for mice with transplanted 
mammary adenocarcinoma, synergistic results are obtained when MTX 
administration precedes 5FU by 6-12 hours, whereas the effects of MTX 
and 5FU given simultaneously or with 5FU preceding MTX are inferior to 
the effects of either drug alone, indicating antagonism. Mulder et. 
al. (40) showed that, for L1210 leukemia and C22LR osteosarcoma in mice, 
sequential treatment with MTX followed in 24 hours by 5FU is both the 
most effective antitumour schedule and the most toxic schedule when 
compared with other schedules in which MTX precedes 5FU by one, three, 
or sixteen hours, 5FU precedes MTX by one, three, sixteen or twenty- 
four hours, or the agents are administered simultaneously. Toxicity 

13 
is mainly gastrointestinal, resulting in diarrhea, weight loss, and, 
ultimately, death. Benz et. al. (3, 4, 5) showed that, for human 
colon adenocarcinoma HCT-8 cells and human breast carcinoma 47-DN 
cells in vitro, there is maximum synergistic inhibition of clonal 
growth when 5FU is given during the last six hours of a 24-hour MTX 
exposure period, whereas shorter pre-treatment intervals or 5-FU pre¬ 
ceding MTX cause merely additive or less-than-additive inhibition. 
Cadman et. al. (13) had shown that L1210 cells in vitro require at 
least three hours of MTX pretreatment prior to 5FU exposure to produce 
greater than additive cytotoxicity; Benz' follow-up work showed that 
HCT-8 cells require at least six hours of MTX pretreatment and that 
47-DN cells require at least 18 hours of MTX pretreatment prior to 
5FU exposure to produce greater than additive cytotoxicity (5). The 
results of the studies cited here are summarized in Table 2, adapted 
from Mulder (40). Clearly, MTX preceding 5FU is superior to other 
MTX-5FU schedules, and is probably a synergistic regimen. The appro¬ 
priate MTX pretreatment interval varies between cell types; tumor 
doubling time is crucial to pretreatment interval effects. Probably, 
for example, the MTX-5FU antagonism found by Waxman et. al., Ullman 
et. al., and Tattersall et. al. in L1210 mouse leukemia cells is due 
to the fact that none of these researchers studied sequencing in which 
MTX precedes 5FU by the minimum three hours found necessary for syner¬ 
gism by Cadman. 
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(1) Bertino et. al. (6,7) originally proposed that high-dose MTX, 
given first, increases the amount of thymidylate synthetase bound as a 
ternary complex to 5FdUMP, possibly by virtue of the MTX itself, 
present in such high levels, acting as an analog of >10_methylene 
THF; the ternary complex proposed would be one of 5FdUMP, MTX, and 
thymidylate synthetase. 
(2) More recently, Cadman, Benz, and their coworkers (3,4,5,13, 
14,15) have shown the following: MTX pre-treatment of L1210 and other 
cells causes dose-related increased intracellular levels of -5FU, 
5FdUMP, and 5FUTP, with a maximal effect of a 5-fold increase in these 
5FU nucleotides occurring six hours after MTX administration in L1210 
cells (14). In both control and MTX-pretreated 47DN cells, 70-75 
percent of the accumulated 5FU was present as 5FUTP, and over 98 percent 
was present as ribonucleotides (5). MTX also causes a dose-related 
increase in intracellular 5-phosphoribosyl-l-pyrophosphate (PRPP) 
pools. In L1210 cells this increase is as much as 8-fold (14). In 
HCT-8 cells, 5FU accumulation is maximally enhanced after three hours of 
MTX pre-treatment, but PRPP levels continue to increase up to 16-fold 
after 72 hours of MTX pre-treatment (4). The elevated PRPP levels are 
presumed to be due to a decrease in the normal feedback control that 
the end products of de novo purine synthesis have on PRPP synthesis; 
the PRPP which would have been utilized for purine synthesis is, in 
the absence of de novo purine synthesis caused by MTX, available for the 
ribosylphosphorylation of 5FU to 5FUMP by orotate phosphoribosyl- 
transferase. This accounts for the increased 5FU nucleotide levels 
found in the presence of MTX. 
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Both 5FdUMP and 5FUTP levels are therefore enhanced by MTX pre- 
treatment. As previously mentioned, both of these compounds are cyto¬ 
toxic; the former inhibits DNA synthesis by inhibiting thymidylate 
synthetase, while the latter is incorporated into RNA, inhibiting pro¬ 
tein synthesis. The relative cytotoxic importance of each varies with 
cell type. The synergistic cytotoxicity of 5FU in the presence of MTX 
is, however, probably more related to the gradual incorporation of 
5FUTP into RNA. Several facts support this: MTX pre-treated 47DN 
cells show a two to three fold increase in 5FUTP incorporation into 
RNA (5). Further, as Ullman et. al. argued, MTX should be antagonistic 
to the effects of 5FdUMP by depleting N^»^-methylene THF. Moreover, 
when 5-fluoro-deoxyuridine, a precursor of 5FdUMP but not of 5FUTP 
(Figure 3), is used in L1210 cells instead of 5FU, there is no com¬ 
parable accumulation of 5FU nucleotides with MTX pre-treatment (14). 
The synergism of MTX and 5FU, therefore, should occur only in cells 
which require PRPP as a ribose and phosphate donor for the formation of 
5FUMP, and not in cells that can form 5FUMP by a pathway independent of 
PRPP, such as the uridine phosphorylase-uridine kinase pathway (Figure 
3), which uses 5-fluorouridine as an intermediate. 
Furthermore, the MTX-5FU synergism should only occur when MTX pre¬ 
cedes 5FU. The appropriate MTX pre-treatment interval depends on the 
rate of intracellular accumulation of PRPP, which varies between dif¬ 
ferent cell types; the degree of synergism also depends on orotate- 




If 5FU precedes MIX, theoretical antagonism should occur; the 
inhibition of thymidylate synthetase prevents the oxidation of 
methylene THF to DHF, preserving the THF pool for de novo purine syn¬ 
thesis, antagonizing the effect of MTX (Figure 5). 
Cadman and Benz have accumulated substantial additional evidence 
in favor of their explanation of MTX-5FU synergism. For example, the 
synergism is not found when leukovorin precedes 5FU administration; 
accumulation of PRPP and 5FU nucleotides is preventable by leukovorin. 
Further, pre-treatment with inhibitors of purine synthesis other than 
methotrexate, including 6-mercaptopurine ribonucleoside, azaserine, 
6- diazo-5-oxo-L-norleucine, and L-alanosine, results in increased intra¬ 
cellular concentrations of PRPP by 15-25 fold over control levels and 
consequent enhanced 5FU nucleotide accumulation (15). Also, 5FU nucleo¬ 
tide accumulation is decreased in mutant cells having increased DHF 
reductase specific activity and/or absent MTX transport (14). Finally, 
7- deazaadenosine, an inhibitor of PRPP synthetase, prevents increased 
PRPP pools and increased 5FU nucleotide accumulation when added to L1210 
cell cultures (14). 
Accepting the existence of a synergistic cytotoxicity when MTX 
precedes 5FU in vitro, several researchers have conducted preliminary 
clinical trials of this regimen in human patients with various types of 
cancers. Wiemann et. al. (54) treated 15 patients with various advanced 
neoplasms with a total of 41 courses of Mhigh-doseM MTX given as an 18- 
hour infusion with 5FU, 600 mg/m^, given as a rapid IV injection at 
hour nine. They found no correlation between toxicity and peak MTX 
levels, but they found that the addition of 5FU resulted in a significant 
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increase in non-hematologic toxicity compared with high-dose MTX alone, 
suggesting synergistic toxicity. Severe toxicity was observed after 
15 percent of the treatment courses, with a white blood cell (WBC) 
count of less than 2,000 cells^Ml being found after five percent, a 
platelet count of less than 50,000/^Ul being found after five percent, 
ulceration of more than 25 percent of the oral mucosa being found after 
ten percent, and severe dermatitis being found after five percent of 
the treatments. One patient died. Mild toxicity was observed after 
another 46 percent of the treatment courses, with mild stomatitis being 
found after 34 percent, conjunctivitis after 17 percent, nausea after 
12 percent, mild dermatitis after 7 percent, diarrhea after 5 percent, 
a platelet count of less than 100,000 after 5 percent, and a WBC count 
of less than 3,000 after 2.4 percent of the treatments. Four patients 
experienced mild alopecia. 
Moayeri et. al. (39) treated 26 patients with diverse malignancies 
with a total of 81 courses of a biweekly regimen of MTX 200 mg/m^ 
o 
infused over four hours, followed three hours later by 5FU 600 mg/m , 
followed by LV 12 mg/m^ every six hours for six doses, starting 24 
hours after the MTX infusion. They found a WBC count of less than 
2,000 in two patients, a WBC count of less than 4,000 in an additional 
11 patients, a platelet count of less than 50,000 in one patient, a 
platelet count of less than 100,000 in an additional three patients, 
and mild to moderate mucositis in two patients. They did not report 
the number of treatments after which each patient developed these side- 
effects. Of 18 patients evaluated for the effectiveness of the treat¬ 
ment, 14 had received prior chemotherapy; 10 of these had received prior 
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MTX or 5FU. No patients showed a complete response to the MTX-5FU 
therapy, but six of the eighteen (33 percent) showed a greater than 
50 percent regression of their tumor with no new lesions appearing. 
These partial responses lasted from one to eleven months, with a mean 
of over four months. Three of the eighteen (17 percent) had a less 
than 50 percent tumor regression, while nine of the eighteen (50 per¬ 
cent) showed no response at all to the therapy. Of the nine who showed 
some response, four had received prior MTX or 5FU. 
Reed et. al. (44) treated 22 patients with disseminated adeno¬ 
carcinoma of various types with a total of 80 cycles of an every three 
to four week regimen consisting of MTX 30 mg/m^ I.V. on day one, 5FU 
1000 mg/m^/day on days one through five as a continuous infusion, and 
O 
chlorambucil 30 mg/m^ p.o. on day five. Four patients were rated as 
having good to excellent performance status at the start of the study, 
and the other 18 had a fair to poor performance status. Ten of the 
twenty-two patients showed no toxicity, two patients developed moderate 
mucositis, four more developed mild mucositis, one patient had severe 
nausea and vomiting, four more had mild nausea and vomiting, and two 
patients showed a WBC count less than 3,000. One patient died, and 
four were lost to follow-up after one treatment cycle. Of the other 
17, none showed a complete response to therapy, but two (12 percent) 
showed a greater than 50 percent tumor regression, with a median 
response duration of 27.5 weeks and a median survival of 52 weeks. 
Nine of the seventeen (53 percent) were stable or improved for at least 
eight weeks, with a median response duration of 18 weeks and a median 

21 
survival of 48 weeks. Six of the seventeen (35 percent) showed no 
response to therapy; their median survival was 20 weeks. 
Pitman et. al. (43) treated 11 patients, all of whom had advanced 
squamous cell carcinoma of the head and neck, with a total of 77 courses 
of an every one to two week regimen consisting of MTX 125-250 mg/m^ 
I.V., followed one hour later by 5FU 600 mg/m^ I.V., followed by LV 
10 mg/m^ p.o. every six hours for six doses, starting 24 hours after 
the MTX infusion. Four of the eleven patients developed diarrhea, two 
patients developed mild to moderate nausea and vomiting, one patient 
developed mild to moderate mucositis, one patient developed dermatitis, 
and one patient developed a WBC count of less than 2,000 and a platelet 
count of less than 100,000. Five of the eleven patients had had no 
prior therapy for their disease. Of the ten evaluable for response to 
the MTX-5FU therapy, all ten (100 percent) showed a greater than 50 
percent tumor regression, usually by the sixth week of therapy, and 
four of the ten (40 percent) showed complete responses. Sequential 
MTX-5FU therefore appears highly effective against squamous cell car¬ 
cinoma of the head and neck. 
The two most extensively studied malignancies in clinical trials 
of sequential MTX-5FU, however, have been colorectal carcinoma and 
breast cancer. The present standard therapy for metastatic colorectal 
cancer, single-agent 5FU, yields only a 20 percent response rate (47). 
Other agents used in combination with 5FU have failed to increase the 
response rate or duration. Isacoff et. al. (32) were the first to treat 
advanced colorectal carcinoma patients with sequential MTX-5FU. They 
treated six patients with an every two to four week regimen consisting 
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of MTX 0.5-3 g. I.V. bolus followed in one hour by 5FU 0.5-3 g., fol¬ 
lowed by LV 15 mg every six hours for eight doses, starting 24 hours 
after the MTX infusion. Four of the six patients had partial 
responses, with three of these four lasting at least six months. 
Biran et. al. (9) treated 31 patients with advanced colorectal 
adenocarcinoma with 56-day cycles consisting of MTX 30 mg/m^ I.V. on 
days 1,8,29, and 36, 5FU 600 mg/m^ I.V. on days 1,8,29, and 36, and 
mitomycin 10 mg/m^ I.V. on day one. The MTX and 5FU were not admini¬ 
stered with any set time-delay between them. The main toxic effects 
were transient myelosuppression, which necessitated 14 hospitalizations, 
and mild to moderate stomatitis, found in 11 patients. No patients 
showed a complete response or a greater than 50 percent tumor regres¬ 
sion in response to this therapy. Five of the thirty-one patients 
showed either a greater than 25 percent reduction in measurable tumor 
or a 25 percent decrease in C.E.A. titer with a greater than 20 percent 
improvement in performance status. Thirteen patients had stable 
disease. The other thirteen patients showed continued disease progres¬ 
sion. The patients with minimal responses or stable disease had a med¬ 
ian survival of 7.5 months, wherease nonresponders had a median survival 
of four months (P = .004). 
Solan et. al. (46,47) treated 30 patients with advanced colorectal 
cancer with a regimen consisting of either MTX 200 mg/m^ I.V. (15 
patients) or MTX 40 mg/m^ I.V. (15 patients) followed in four hours by 
5FU 600 mg/m^ I.V. Patients receiving high-dose MTX were given LV 
30 mg/m^ I.M. once and then 10 mg/m^ p.o. every six hours for eight 
doses, starting 24 hours after the MTX infusion. Each group received 
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treatments weekly for four weeks and every two weeks thereafter. Treat 
ment was withheld for a WBC count of less than 4,000, a platelet count 
under 100,000, or severe mucositis. Of the 13 patients evaluable for 
toxicity in the higher-dose MTX group, eight developed ECOG grade three 
or higher (41) hematologic toxicity. Six of these had fever and leuko¬ 
penia; three of these had documented septicemia. Two of these died as 
a result, both early in the study, when LV rescue was with a regimen of 
only 10 mg/m^ I.M. once and then 10 mg/m^ p.o. every six hours for six 
doses. Nine of the thirteen patients developed serum creatinines 
greater than 50 percent above their baseline levels. Two of the thir¬ 
teen were hospitalized for intractable vomiting, and one of the thir¬ 
teen developed severe stomatitis. All of the first seven patients 
treated in the high-dose MTX group had moderate to severe toxic side- 
effects. In response to this, the LV rescue dose was amended as above, 
and patients in this group subsequently had their urine alkalinized 
with NaHC03 3 g p.o. QID and acetazolamide 250 mg p.o. QID from one 
day before to two days after the MTX infusion. MTX was withheld unless 
the urine pH exceeded 7. Among the 15 patients receiving lower-dose 
MTX, only one developed severe myelosuppression, and one was hospital¬ 
ized for intractable vomiting. None developed septicemia or azotemia. 
The authors conclude that high-dose MTX with 5FU causes unacceptable 
toxicity. 
No patient in the Solan study who had received prior chemotherapy 
responded to either regimen. Among those without prior chemotherapy, 
there were no complete remissions. Two of the six patients in the high 
dose MTX group who had not received prior chemotherapy showed a greater 
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than 50 percent decrease in the cross-sectional area of measurable 
lesions; these partial responses lasted four and 12+ months. Three of 
the eight patients in the low-dose MTX group who had not received prior 
chemotherapy showed such partial responses; these lasted four, five 
and eight months. Given the small number of patients studied, these 
results are not statistically different from the historical response 
rate of 20 percent to 5FU alone in the treatment of colorectal cancer. 
Kerney et. al. (33) treated previously untreated colorectal car¬ 
cinoma patients with a regimen consisting of MTX 40 mg/m^ I.V. fol- 
O 
lowed in 24 hours by 5FU 600 mg/m^ I.V., on days one and eight of 
every month. They found minimal myelosuppression, but a 60 percent 
incidence of mucositis. Thirty-four percent of the patients studied 
had partial responses to the therapy. 
Sequential MTX-5FU has also been studied by several workers in 
clinical trials on breast cancer patients. Tisman et. al. (49) treated 
20 patients with advanced breast cancer who had failed traditional CMF 
or FAC therapy with one of two regimens: 13 patients received MTX 
1500 mg/m^ I.V., followed in one hour by 5FU 1500 mg/m^ I.V., followed 
by LV 15 mg. p.o. every six hours for eight doses, starting 24 hours 
after the MTX infusion. Seven patients received MTX 500-1000 mg I.V. 
followed in one hour by 5FU 500-1000 mg I.V., followed by LV as above. 
Mild leukopenia was common in both groups. Three of thirteen patients 
in the higher dose MTX-5FU group developed mucositis. Two patients in 
this group developed blurred vision and dizziness. One patient in the 
lower-dose group died. Eight of the twenty total patients (40 percent) 
showed partial responses to the therapy, lasting from two to ten weeks 
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(mean = seven weeks). Another eight (40 percent) had complete relief 
of bone pain caused by metastases, and a consequent return to normal 
activity lasting for one to twenty-four weeks (mean = twelve weeks). 
Gerwitz and Cadman (27) treated 17 patients with advanced breast 
cancer with 28-day cycles consisting of MTX 200mg/m^ I.V., followed 
one hour later by 5FU 600 mg/m^ I.V., followed by LV 10 mg/m^ p.o. 
every six hours for six doses, starting 24 hours after the MTX infusion; 
this regimen was administered on days one and eight of every 28-day 
cycle. Toxicity was minimal and transient, with one patient developing 
mucositis, two patients developing nausea and vomiting, and no patients 
exhibiting a WBC count of less than 2,000. One of the seventeen patients 
had a complete response, eight additional patients showed at least a 
50 percent tumor regression, and two patients showed a lesser partial 
response. Three of the eleven responders had been refractory to stan¬ 
dard MTX-5FU therapy. In fact, neither prior therapy nor hormonal 
status correlated with response except for prior MTX or 5FU therapy. 
The 11 of 17 (64 percent) response rate is obviously impressive. 
Based on their work showing that human 47DN breast cancer cells 
in vitro require 18 to 24 hours of MTX pre-treatment prior to 5FU expo¬ 
sure to produce synergistic cytotoxicity, Benz, Cadman, et. al. (5) 
next treated seven patients with advanced malignancies, four of whom 
had breast cancer, with a total of 21 courses of an every one to two 
week regimen consisting of MTX 50 mg/m^ p.o. every six hours for five 
doses, 5FU 600 mg/m^ I.V. one hour following the last MTX dose (and 
hence 25 hours following the first MTX dose), and LV 10 mg/m^ p.o. every 
six hours for six doses starting six hours after the last MTX dose (30 
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hours after the first MTX dose). Six of the seven patients had pre¬ 
viously been involved in the one-hour sequential MTX-5FU study (27). 
Toxicity for the 24-hour sequential regimen was related to retreatment 
interval, not cumulative drug dose or serum MTX level. As a result, 
retreatment was delayed but drug dosages were not altered for those 
patients manifesting toxic side-effects. Eight of the 21 treatment 
courses (38 percent) resulted in no toxicity. Another eight of the 
21 (38 percent) resulted in mild mucositis. Six of the 21 (28 percent) 
resulted in mild leukopenia, while two of the 21 (10 percent) resulted 
in severe leukopenia, with a WBC count of less than 2,000^ul. There 
was a three out of 21 (14 percent) incidence of mild nausea and 
vomiting, and a three out of 21 (14 percent) incidence of mild diarrhea. 
Such mild toxicity is in contrast to the results of 24-hour MTX-5FU 
sequencing tried in tumor-bearing mice by Mulder et. al. (40), and in 
colorectal carcinoma patients by Kerney et. al. (33). 
The results of the clinical trials of sequential MTX-5FU cited 
here are summarized in Table 3. 
The present study is essentially a continuation of the Benz-Cadman 
24-hour sequential MTX-5FU trial (5), whose preliminary results are 
summarized above. Many more patients have been treated and the results 
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MATERIALS AND METHODS 
Twenty-three patients with various advanced neoplasms received a 
total of 127 courses of a regimen consisting of MTX 50 mg/m^ p.o. every 
six hours for five doses (24 hours), 5FU 600 mg/m I.V. bolus one hour 
after the last MTX dose (25 hours after the first MTX dose), and LV 
o 
10 mg/m p.o. every six hours for six doses, beginning six hours after 
the last MTX dose (30 hours after the first MTX dose). In addition, 
three of these patients received a total of eight courses of a regimen 
consisting of MTX 8 mg/m^ p.o. every six hours for five doses, followed 
by 5FU as above and without LV rescue. The mean interval between treat¬ 
ments was 20.4 "t 9.4 days; treatments usually were administered every 
two weeks, but were postponed if toxicity developed. Clinical and 
laboratory evaluations were performed prior to each treatment. 
Eligibility required a WBC count >4000/xnm^, a platelet count 
>100,000/mm3, a creatinine clearance >60 ml/minute and/or a serum cre¬ 
atinine <1.5 mg/dl, and a hemoglobin concentration >11 g/dl. The patients 
ranged in age from 34 to 72, with a mean age of 56 years. Twenty-one of 
the twenty-three had received prior chemotherapy for their disease. 
Nineteen of these twenty-one had received prior MTX and/or 5FU, includ¬ 
ing 12 who had previously received one-hour sequential MTX-5FU therapy. 
Eleven of the twenty-three patients had breast cancer, five patients 
had colorectal adenocarcinoma, three suffered from mycosis fungoides, 
one had a hepatoma, one had an adenocarcinoma of unknown primary, and 
two had squamous cell carcinoma of the head and neck, one involving the 




Toxicity and performance status were evaluated by the Eastern 
Cooperative Oncology Group criteria (41), as outlined in Table 4. At 
the start of 24-hour MTX-5FU sequential therapy, 20 of the 23 patients 
had ECOG performance statuses of 0 or 1, while three patients had per¬ 
formance statuses of 2,3 or 4. 
5FU was obtained from Roche Laboratories (Nutley, N.J.), and MTX 
and LV were obtained from the Division of Cancer Treatment, National 
Cancer Institute (Bethesda, MD.). 
Trough and peak serum MTX levels were measured by enzymatic inhi¬ 
bition of dihydrofolate reductase (25) one hour before and one hour 
after the fifth MTX dose during 54 of the treatment courses, early in 
the study. This assay is sensitive to O.Oly^M MTX and has been shown 
to correlate well with other techniques for MTX determination (1). 
Selected patients also had serum MTX levels measured one hour after the 
initial oral dose. This mean value and the mean peak and trough values 
determined before and after the fifth MTX dose are recorded in Figure 6, 
provided to me by Dr. Chris Benz. A single patient, started on therapy 
in the hospital, had multiple MTX measurements following each of the 
five oral MTX doses. These values confirmed the reports of others (22, 
30,38) that peak serum levels occur about one hour after each oral dose, 
with trough values falling to 25-50 percent of peak values, and that 
peak values during divided dose schedules do not differ significantly 
from each other. These observations justify the interpolated curve in 
Figure 6. 
Thirteen of the 23 patients in the study received four or more 
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Figure 6. MTX Kinetics 
Solid line - Mean serum MTX levels following oral MTX, 50 mg/m2, at 
0,6,12,18, and 24 hours, 1 S.D. (J), with an interpolated 
curve. 
Broken Line - Serum MTX levels following X.V. bolus MTX, 250 mg/m2 as 
reported by Henderson et. al. (30). 

RESULTS 
I. Toxicity of the Regimen 
The toxicity resulting from 24-hour sequenced MTX and 5FU is sum¬ 
marized in Table 5, according to the ECOG criteria already outlined. 
Fifty-eight of the 135 treatment courses (43 percent) resulted in one 
or more forms of toxicity, with the other 57 percent of treatments com¬ 
pletely benign. There were no deaths due to toxic side-effects of 
therapy, and no patient discontinued the regimen on his or her own, 
although one patient was granted a request to discontinue the therapy 
after persistently exhibiting nocturnal diarrhea five to six days out 
from therapy. By far the most common side-effects were mild (ECOG 
Grade I-II) anemia and leukopenia, occuring after 17.8 percent and 
14.9 percent of the treatment courses, respectively. No other side- 
effect occurred more than ten percent of the time. Mild nausea/vomiting, 
diarrhea, mucositis, thrombocytopenia, and renal toxicity each occurred 
after eight to ten percent of the treatment courses. Mild fevers were 
even less common (three percent), as were mild infections: one female 
patient experienced a mild urinary tract infection during therapy, and 
one other patient experienced a mild gum infection during therapy, sub¬ 
sequent to root canal work. Four of the 13 cases of Grade I renal 
toxicity were recorded for one patient who had underlying Grade I renal 
impairment prior to therapy. One case of Grade I nausea-emesis occurred 
in a patient only after bromocriptine 2.5 mg. p.o. QID was added to her 
treatment regimen. 
All toxic effects of the MTX-5FU regimen were mild (ECOG Grade I-II) 
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her first two courses of the regimen, which were administered one week 
apart. This patient developed Grade II nausea-ernesis, Grade II anemia, 
Grade I diarrhea, Grade III mucositis, Grade IV leukopenia, and a Grade 
III infection (streptococcal pharyngitis) which necessitated a nine- 
day hospitalization. Therapy was resumed three weeks subsequent to 
the second treatment course. Later treatment courses, at two week 
intervals, resulted in no worse than Grade I toxicity except for occa¬ 
sional Grade II fevers one day out from therapy. 
Other mild but uncommon toxic side-effects of the MTX-5FU regimen 
included the following: 
One patient experienced one episode of increased serum bilirubin 
levels to 2.81 mg7> "direct" and 6.62 mg% "total," with normal SGOT and 
alkaline phosphatase levels. The patient’s bilirubin level soon dropped 
to 0.05 mgT. direct and 0.72 mg% total. 
Another patient exhibited a gradual, persistent eight month rise 
in liver function parameters from baseline levels of a bilirubin of 
0.10/0.36 mg7o, an SGOT of 19 units, and an alkaline phosphatase of 49 
units to a bilirubin level of 2.55/4.96, an SGOT of 339, and an alka¬ 
line phosphatase of 92. However, this patient, who has adenocarcinoma 
of the rectum, has documented liver metastases and has had questionable 
episodes of biliary colic and small bowel obstruction, so the rise in 
her liver function parameters may not necessarily be due, all or in 
part, to the MTX-5FU therapy. 
One breast cancer patient with known cerebral metastases exhibited 
mild confusion and slight ataxia. These may have been due either to 
5FU toxicity or new cerebellar metastases. 
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Two patients experienced mild hair-loss and epiphora with crusting, 
lasting three to four days, and occurring one week subsequent to ther¬ 
apy. These symptoms were greatly diminished in one of these patients 
when her MTX regimen was decreased from 50 mg/m^ p.o. every six hours 
for five doses to 8 mg/m^ p.o. every six hours for five doses, with 
leukovorin being discontinued and 5FU being administered at the same 
dosage and sequencing. 
One patient with adenocarcinoma of the colon and liver metastases 
received 13 courses of sequential MTX-5FU with no discernable side- 
effects except for an exacerbation of his gout. This is a noteworthy 
and predictable side-effect of the decrease in de novo purine synthesis 
caused by MTX. Allopurinol and other medications used to treat gout 
have the opposite effect: they salvage purines (hypoxanthine, in the 
case of allopurinol). 
Table 6 shows that the occurrence of toxicity did not correlate 
with mean trough or peak serum MTX levels in the study group. Except 
for the above-mentioned woman with alopecia and epiphora, side-effects 
were controlled by prolonging the intervals between treatments, not by 
decreasing drug dosages. 
II. Effectiveness of the Regimen 
Thirteen of the 23 patients in the study received four or more 
courses of therapy and are therefore evaluable for their response to it. 
Eight of these 13 had breast cancer, four had colorectal adenocarcinoma, 
and one had an adenocarcinoma of unknown primary. 
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Table 6. Treatment Courses, Toxicity, and Serum MTX Levels 
for Treatment Courses in Which MTX Levels Were Monitored 
Group A Group B 
Total 
(A+B) 
No. of patients 13 5 18 
No. of treatment 
courses with (+) 
and without (-) 
toxicity 
27 (+) 13 ( —) 14 ( — ) 54 
Serum MTX Level 
(mean + S.D.) 
Trough yuM 
Peak yuM 
1.09 t 0.63 
2.43 t 1.62 
0.82 ± 0.38 
2.95 t 2.24 
0.88 ± 0.79 
2.63 t 1.89 
0.96 ± 0.64 
2.57 t 1.88 
Group A includes patients who experienced some form of MTX toxicity. 
Group B includes those patients who had no toxicity. 
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(A) Effectiveness against breast cancer 
All eight of the breast cancer patients evaluable for response to 
the therapy had ECOG performance statuses of 0 or 1 at the start of the 
therapy, as defined in Table 4. Six of the eight women were post¬ 
menopausal, while two of the eight were pre-menopausal. Six of the 
eight had tumors which were positive for estrogen receptors; all six 
received some form of anti-estrogen therapy. Two of the eight had 
tumors which were negative for estrogen receptors. All eight women had 
known metastases at the start of the protocol. Seven of the eight had 
had mastectomies, and six of the eight had received previous radiation 
therapy. All eight had received some sort of prior chemotherapy beyond 
hormonal therapy. Two of the eight had never before received MTX or 
5FU. One of the eight had received prior MTX but not 5FU, one more had 
received prior MTX and 5FU in a non-sequential regimen, and four had 
previously received one-hour sequential MTX-5FU. The length of time 
each had carried a diagnosis of breast cancer varied from one to 13 
years, with a mean of 4.9 + 3.7 years, at the start of the protocol. 
Table 7 summarizes their response to the protocol. 
Overall, four of the eight patients showed, and continue to show, 
no evidence of recurrent disease on the 24-hour MTX-5FU regimen, for 
a 50 percent "response" rate, where lack of disease progression is 
defined as a partial, if minimal, response to therapy. These responses 
range from four to 13 months in duration, with a mean exceeding seven 
months. One of the four non-responders died five months after starting 
the regimen; the other three are still alive seven to 13 months (mean 
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inferior to that reported by Gerwitz et. al. (27) for one-hour sequenced 
MTX-5FU in breast cancer patients. He reported a 53 percent incidence 
of more than 50 percent tumor regression, and an 11 percent additional 
incidence of lesser partial responses. However, since the Gerwitz 
study involved only 17 patients and these data include only eight 
patients, both studies are too small for definite conclusions about 
effectiveness to be drawn quantitatively. 
One of the two estrogen-receptor-negative patients responded to 
the regimen, while three of the six estrogen-receptor-positive patients 
responded; both are 50 percent response rates. Again, the numbers 
involved are too small to argue against the data of Chang et. al. (19), 
which showed ER-positive tumors much more sensitive to non-sequential 
CMF therapy than ER-negative tumors. 
One of the two pre-menopausal patients responded to the regimen, 
while three of the six post-menopausal patients responded. Again, both 
are 50 percent response rates based on numbers too small to argue 
against the study (42) showing Off to be effective mainly in pre¬ 
menopausal women. 
Both patients who had never before been exposed to MTX or 5FU 
responded to the regimen. In one of these, decreased nodal size was 
noted in response to the 24-hour MTX-5FU. In addition, the patient who 
had previously not been exposed to 5FU and who had only briefly been 
exposed to MTX responded to the regimen. 
In contrast, only one of the five patients who had previously been 
treated with both MTX and 5FU responded to the regimen. This 20 percent 
response rate versus the 100 percent response rate of those patients 
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never previously treated with MTX-5FU is, while based on small numbers, 
suggestive of an increased effectiveness of the new MTX-5FU regimen in 
patients who have not already failed an old MTX-5FU regimen. Those who 
have failed an old MTX-5FU regimen may have tumors that are more resis¬ 
tant to MTX-5FU than most. Similar results were noted by Gerwitz and 
Cadman (27). 
(B) Effectiveness against colorectal adenocarcinoma 
All four of the colorectal cancer patients evaluable for response 
to the therapy had ECOG performance statuses of 0 or 1 at the start of 
the therapy. All four had known metastases at the start of the protocol. 
Three of the four had received prior chemotherapy involving 5FU, either 
alone or in combination with other drugs. The fourth had received no 
prior chemotherapy. None had previously been exposed to MTX. Table 8 
summarizes these patients' histories and their response to the regimen. 
Overall, three of the four patients showed, and two continue to 
show, no disease progression on the 24-hour MTX-5FU regimen, for a 75 
percent "responsd1rate. One patient responded for eight months with 
decreased hepatomegaly and a decreased CEA titer, until a frontal lobe 
mestastasis was noted on C-T scan. The other two patients continue to 
respond, with response durations exceeding eight and four months. The 
non-responding patient died four months after starting the regimen. 
This 75 percent response rate is much higher than the historical 
response rate of 20 percent to 5FU alone in the treatment of colorectal 
cancer, and is also higher than the response rates noted by Solan (46, 
47) and Kerney (33) to sequential MTX-5FU regimens against colorectal 
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cancer. However, the small number of patients involved in this study 
precludes definite conclusions. 
Two of the three patients who had previously been treated with 
5FU responded to the regimen. In one, the CEA titer fell from 105 to 
12.6. The patient who had received no prior chemotherapy responded for 
eight months until progressive disease was detected. 
One patient with an adenocarcinoma of unknown primary received 
extended treatment with 24-hour sequential MTX-5FU. The patient is 
a 67-year-old woman whose disease was diagnosed three years prior to 
starting the protocol when a pulmonary metastasis was biopsied. In 
addition to progressive pulmonary metastases, she has a metastasis at 
her right sacro-iliac joint. Prior therapy included 5FU, adriamycin, 
and mitomycin for ten eight-week cycles, 5FU and adriamycin alone for 
14 three-week cycles, and a regimen of cis-platinum, vincristine, and 
cyclophosphamide for five months. She received five courses of 24- 
hour sequential MTX-5FU at two week intervals. Her ECOG performance 
status was 0 both at the start and at the end of this therapy, but her 
MTX-5FU therapy was discontinued in favor of ifosfamide after five 
courses in response to continued tumor progression on chest x-ray. 
She is therefore a treatment failure. 

DISCUSSION 
The present study, a continuation of the preliminary study by 
Benz, Cadman, et. al. (5), is the second to study the effects of a 
MTX-5FU regimen sequenced at 24-hours. Most previous sequential MTX- 
5FU trials involved one-hour sequencing (27,32,43,49). Solan et. al. 
(47) used four-hour sequencing. Moayeri et. al. (39) studied seven- 
hour sequencing. Kerney and Michaelson (33) were the others to study 
24-hour sequencing. 
Although the number of patients in the present study is too small 
for definite conclusions concerning the efficacy of the regimen, some 
observations may be made, at least. The 50 percent "responsd1 rate noted 
among breast cancer patients is inferior to that reported by Gerwitz 
et. al. (27), who treated breast cancer patients with one-hour sequen¬ 
tial MTX-5FU and noted a 64 percent partial response rate. The 50 per¬ 
cent rate is, however, superior to the 40 percent partial response rate 
reported by Tisman et. al. (49), who also treated breast cancer patients 
with a one-hour MTX-5FU sequenced regimen. No difference in response 
rates was seen in the present study between women with ER-positive and 
ER-negative tumors, or between pre-menopausal and post-menopausal 
patients; all had 50 percent response rates based on the small patient 
sample. We define "response" in this study as stable disease. 
More interesting is that all three of the breast cancer patients 
never before exposed to a MTX-5FU containing regimen responded to treat¬ 
ment, while only one of five patients who had previously been treated 




results. Prior exposure to MTX and 5FU clearly decreases the possi¬ 
bility of further response to a new regimen containing the drugs. 
The 75 percent "response” rate noted among colorectal cancer patients 
in this study is much higher than the historical 20 percent response 
rate to 5FU alone against colorectal cancer. It is also higher than 
the 18 percent partial response rate of colorectal cancer patients 
noted by Solan et. al. (46,47), who used four-hour MTX-5FU sequencing, 
and the 34 percent partial response rate of colorectal cancer patients 
noted by Kerney et. al. (33), who used 24-hour MTX-5FU sequencing. It 
is more in agreement with the six-patient study of Isacoff et. al. (32), 
who used one-hour MTX-5FU sequencing in colorectal cancer patients and 
found partial responses in four of six (67 percent) cases. Again, 
however, there are only four colorectal cancer patients evaluable for 
response in the present study. Studies involving larger numbers of 
patients would be necessary to draw clear conclusions about the efficacy 
of this regimen. 
Further studies, too, might address some other interesting ques¬ 
tions to increase the regimen's efficacy. For example, instead of 
using merely MTX and 5FU, a future worker on breast cancer might con¬ 
sider using the more common "CMF" drug regimen, but with 24-hour sequenc¬ 
ing of the MTX and 5FU. 
Moreover, there should be nothing set in cement about the 24-hour 
time interval. Rather, it would be best to determine the proper time 
intervals for treating different cancers based on in vitro work. This 
is because variations in tumor growth rates are crucial to the cyto¬ 
toxicity of sequential MTX-5FU therapy. For example, Benz, Cadman et. 
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al. (5) have shown that human 47DN breast cancer cells in vitro require 
18 to 24 hours of MTX pre-treatment prior to 5FU exposure to produce 
optimal synergistic cytotoxicity. HCT-8 colorectal cancer cells, on 
the other hand, require only 6 to 12 hours of pre-treatment, and L1210 
leukemia cells require only three hours of pre-treatment to produce 
optimal results. Tumors with different doubling times differ in the 
rate of intracellular PRPP and therefore 5FU nucleotide accumulation 
caused by MTX pre-treatment; orotate phosphoribosyltransferase activity 
also differs between different cell types. That these factors are 
crucial is illustrated by the fact that Waxman et. al. (53), Ullman 
et. al. (50), and Tattersall et. al. (48) all found MTX-5FU antagonism 
in L1210 leukemia cells in vitro because none studied MTX-5FU sequencing 
intervals greater than the minimum three hours found necessary for 
synergism by Cadman. 
The toxicity found to be caused by the MTX-5FU regimen in the 
present study is lower than that found by most previous investigators. 
For example, Mulder et. al. (40), who studied 24-hour MTX-5FU sequencing 
in tumor bearing mice, found it to be quite toxic. Wiemann et. al. 
(54), who infused 5FU at hour nine of an 18-hour MTX infusion, noted a 
15 percent incidence of severe hematologic or gastrointestinal toxicity. 
Kerney et. al. (33), who studied 24-hour MTX-5FU sequencing, noted mini¬ 
mal myelosuppression but a 60 percent incidence of mucositis. Solan et. 
al. (46,47), who studied the effects of a four-hour sequencing interval, 
noted the worst toxicity of all: eight of 13 patients (62 percent) given 
200 mg/m^ of MTX developed ECOG grade 3 or higher hematologic toxicity, 
with three of these developing septicemia and two of these dying. Nine 
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of the 13 (69 percent) developed serum creatinines more than 50 percent 
above their baseline levels. Two of the 13 were hospitalized for 
intractable vomiting, and one developed severe stomatitis. 
Intermediate levels of toxicity were found by Moayeri et. al. (39), 
who studied seven-hour sequencing and found a 12 percent incidence of 
severe hematologic toxicity. Similarly, Pitman et. al. (43), studying 
the effects of a one-hour MTX-5FU sequencing, found a nine percent 
incidence of severe hematologic toxicity. 
In marked contrast, the present study found only a 1.5 percent 
incidence of severe toxicity of any sort, and this was found only in 
the initial response to the therapy of a single patient, who later 
tolerated the therapy quite well. These results are in agreement with 
the results of Tisman et. al. (49) and Gerwitz et. al. (27), who studied 
one-hour MTX-5FU sequencing and found only mild toxicity. 
The goal of all these investigators, of course, is to increase 
tumor cytotoxicity without increasing toxicity to normal tissues. One 
way of relieving excessive toxicity, had we found it, would have been 
to, as Solan et. al. (46,47) did, administer leukovorin in larger doses 
and/or intramuscularly. Another method they used was to alkalinize the 
patients' urine with sodium bicarbonate and acetazolamide from one day 
before to two days after the MTX infusion. Alternatively, the MTX 
dosage may be decreased, or, as was the practice in the present study, 
the retreatment interval may be prolonged. 
Future workers might use these or more novel methods to decrease 
MTX toxicity, still under investigation. For example, differences in 
the susceptibilities of different tumors and different tissues to a 
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MTX-5FU regimen are possibly due to differences in the kinetic charac¬ 
teristics of the purine salvage enzymes in the different tissues. 
"Salvage" purines, such as hypoxanthine, inosine, and adenosine, can 
antagonize the effects of de novo purine inhibitors, such as MTX (14). 
A possible way of averting excess toxicity of an MTX-5FU regimen would 
be to determine, through stem cell assays, if there are plasma hypo¬ 
xanthine levels that will selectively protect bone marrow from MTX 
toxicity without protecting tumor cells, and to aim for those levels 
using agents such as allopurinol, probenicid, sulfinpyrazone, and 
salicylates to increase circulating levels of hypoxanthine. Similarly, 
stem cell assays comparing the toxicity of sequential MTX-5FU to normal 
human marrow with its toxicity to freshly resected tumor specimens might 
possibly reveal the ideal MTX levels to aim for in cancer chemotherapy, 
and would therefore be important to further rational design of chemo¬ 
therapy protocols using MTX and 5FU (5). 
For the present, the regimen of oral MTX in low-dose, divided 
doses used in this study seems to be an effective means of administer¬ 
ing tumorcidal doses of MTX over 24 hours without causing excessive host 
toxicity. Waxman et. al. (52) showed that maximal effects on de novo 
DNA synthesis are produced in vitro by MTX concentrations of ly^M. 
Cadman et. al. (13) showed that L1210 cells require peak MTX concentra¬ 
tions of from 5y*M to lOy^M for enhanced intracellular accumulation of 
5FU nucleotides and synergistic cytotoxicity to occur. Most previous 
workers attempted to achieve micromolar levels of MTX through bolus 
intravenous infusions of either 40 mg/m^ (low-dose MTX) or 200 mg/m^ 
(high-dose MTX). However, bolus I.V. administration of MTX 40 mg/m^ 
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achieves serum levels greater than lyuM for less than two hours, and 
maintains levels greater than O.lyuM for approximately 24 hours (30). 
Bolus administration of MTX 250 mg/m^ sustains serum levels above 1y^M 
for 24 hours, but is associated with increased host toxicity (8). The 
present study shows that oral MTX in divided doses is an effective and 
convenient method of achieving sustained micromolar blood levels of 
MTX, offering an alternative to bolus high-dose and continuous low-dose 
intravenous infusions. The peak MTX concentrations achieved in this 
study ranged around 2.6yuM, and the trough concentrations ranged around 
ly^M (Table 6). McVie et. al. (38) have shown that repeated oral admini¬ 
stration of MTX, 50 mg/m^, as in this study, results in a series of 
similar peak and trough serum concentrations, permitting the interpolated 
curve of serum values between one and 24 hours of therapy shown in 
Figure 6. For comparison, a curve depicting the peak concentration and 
serum half-life of a total equivalent (250 mg/m^) I.V. bolus of MTX is 
also shown. The divided oral dose schedule over 24 hours conveniently 
achieves and sustains the same micromolar serum levels of MTX as bolus 
infusion of high-dose MTX, but avoids the extremely high peak concen¬ 
trations of bolus infusion, which may contribute to MTX toxicity, 
especially nephropathy. Certainly, the divided oral dose schedule is 
more convenient than intravenous infusion for an outpatient. 
Since oral administration of MTX over 24 hours appears to be a 
safe and effective means of sequencing the drug with 5FU in an out¬ 
patient population, a phase II study comparing high and low dose oral 
MTX sequenced at 24 hours with 5FU appears warranted. 
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